The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma - A review of the literature.

Crit Rev Oncol Hematol

Portsmouth Hospitals University NHS Trust, Portsmouth, England PO6 3LY, UK; Caribbean Cancer Research Institute, Chanka Trace El Socorro South, Trinidad and Tobago. Electronic address:

Published: April 2024

Paraneoplastic neurological syndromes (PNS) are rare neurological disorders arising from malignancy-triggered autoimmunity, yet their association with urothelial carcinoma remains unclear. This systematic review intends to explore any connection, alongside patient/clinical features and management. A literature search identified 25 cases of bladder and upper tract carcinoma linked to PNS. Overall, while infrequent, a meaningful association between PNS and urothelial carcinoma was found in that 84% of cases met a 'possible'-or-'higher-likelihood' PNS diagnosis. Most cases presented with high-risk PNS phenotypes, predominantly cerebellar syndromes and encephalomyelitis/sensory neuronopathy, ∼17 months within cancer diagnosis/recurrence. Review findings suggest a female preponderance in suspected PNS despite higher male incidence of urothelial cancer. Main treatments consisted of surgery alongside chemotherapy or immunotherapeutics (IVIG and/or corticosteroids), which improved symptoms for a slight majority (60%). Ultimately, while common PNS-associated neoplasms should always first be excluded in suspected PNS, in the absence of alternative causes, urothelial carcinomas do merit clinical consideration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2024.104314DOI Listing

Publication Analysis

Top Keywords

urothelial carcinoma
12
paraneoplastic neurological
8
neurological syndromes
8
pns
8
syndromes pns
8
pns urothelial
8
suspected pns
8
urothelial
5
association paraneoplastic
4
carcinoma
4

Similar Publications

Limited research into the tumor immune microenvironment (TIME) for bladder urothelial carcinoma (BUC), particularly the neglect of the intratumoral microbiota, has hindered the development of immunotherapies targeting BUC. Here, we collect 401 patients with BUC with host transcriptome samples and matched tumor microbiome samples from The Cancer Genome Atlas database. Besides, two independent BUC cohorts receiving immunotherapy were obtained.

View Article and Find Full Text PDF

Objective: Our study assessed the correlation between discrepancies in clinical and pathological T stages and overall survival (OS) in patients with upper urinary tract urothelial carcinoma (UTUC), including renal pelvis (UCP) and ureter (UCU) carcinoma, treated with radical surgery.

Methods: We utilized data from the Japanese Hospital-Based Cancer Registry (HBCR) to identify UTUC cases (n = 2376), consisting of UCP cases (n = 1196) and UCU cases (n = 1180), diagnosed with cTa-3N0M0 between 2012 and 2013. All cases were histologically confirmed and treated solely with radical surgery, excluding any chemotherapy or radiotherapy.

View Article and Find Full Text PDF

Introduction: Local recurrence for upper tract urothelial carcinoma typically occurs within 2 years post-surgery. We report a rare case of retroperitoneal recurrence as squamous cell carcinoma 10 years after nephroureterectomy.

Case Presentation: A 67-year-old female was referred to our urology department for a left ureteral tumor.

View Article and Find Full Text PDF

Introduction: Gastroenterocolitis is one of the adverse events related to immune checkpoint inhibitors. However, inflammation of the intestinal lesion used for urinary diversion is not well known as an adverse event related to their use.

Case Presentation: A patient with metastatic bladder cancer was administered pembrolizumab as second-line treatment.

View Article and Find Full Text PDF

Introduction: Laser ablation using a 980-nm wavelength diode laser, which is a new-generation laser, for recurrent bladder cancer is known to have a lower incidence of complications and recurrence than conventional transurethral resection of bladder tumor surgery. This is the first study to report the use of 980-nm diode laser ablation for recurrent non-muscle-invasive bladder cancer in Japan.

Case Presentation: A 73-year-old man underwent transurethral laser ablation for the treatment of recurrent non-muscle-invasive bladder cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!